title: AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.
abstract: Hepatitis C virus (HCV) enters its target cell via clathrin-mediated endocytosis. AP-2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK) are host kinases that regulate clathrin adaptor protein (AP)-mediated trafficking in the endocytic and secretory pathways. We previously reported that AAK1 and GAK regulate HCV assembly by stimulating binding of the μ subunit of AP-2, AP2M1, to HCV core protein. We also discovered that AAK1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, could block HCV assembly. Here, we hypothesized that AAK1 and GAK regulate HCV entry independently of their effect on HCV assembly. Indeed, silencing AAK1 and GAK expression inhibited entry of pseudoparticles and cell culture grown-HCV and internalization of Dil-labeled HCV particles with no effect on HCV attachment or RNA replication. AAK1 or GAK depletion impaired epidermal growth factor (EGF)-mediated enhanced HCV entry and endocytosis of EGF receptor (EGFR), an HCV entry cofactor and erlotinib's cancer target. Moreover, either RNA interference-mediated depletion of AP2M1 or NUMB, each a substrate of AAK1 and/or GAK, or overexpression of either an AP2M1 or NUMB phosphorylation site mutant inhibited HCV entry. Last, in addition to affecting assembly, sunitinib and erlotinib inhibited HCV entry at a postbinding step, their combination was synergistic, and their antiviral effect was reversed by either AAK1 or GAK overexpression. Together, these results validate AAK1 and GAK as critical regulators of HCV entry that function in part by activating EGFR, AP2M1, and NUMB and as the molecular targets underlying the antiviral effect of sunitinib and erlotinib (in addition to EGFR), respectively.
  
  
  OBJECTIVE
  Understanding the host pathways hijacked by HCV is critical for developing host-centered anti-HCV approaches. Entry represents a potential target for antiviral strategies; however, no FDA-approved HCV entry inhibitors are currently available. We reported that two host kinases, AAK1 and GAK, regulate HCV assembly. Here, we provide evidence that AAK1 and GAK regulate HCV entry independently of their role in HCV assembly and define the mechanisms underlying AAK1- and GAK-mediated HCV entry. By regulating temporally distinct steps in the HCV life cycle, AAK1 and GAK represent "master regulators" of HCV infection and potential targets for antiviral strategies. Indeed, approved anticancer drugs that potently inhibit AAK1 or GAK inhibit HCV entry in addition to assembly. These results contribute to an understanding of the mechanisms of HCV entry and reveal attractive host targets for antiviral strategies as well as approved candidate inhibitors of these targets, with potential implications for other viruses that hijack clathrin-mediated pathways.
authors: Department of Medicine, Division of Infectious Diseases and Geographic Medicine, and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
authors: Gregory
authors: G
authors: Neveu
authors: Department of Medicine, Division of Infectious Diseases and Geographic Medicine, and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
authors: Amotz
authors: A
authors: Ziv-Av
authors: Department of Medicine, Division of Infectious Diseases and Geographic Medicine, and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
authors: Rina
authors: R
authors: Barouch-Bentov
authors: Department of Medicine, Division of Infectious Diseases and Geographic Medicine, and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
authors: Elena
authors: E
authors: Berkerman
authors: Cell Sciences Imaging Facility, Stanford University School of Medicine, Stanford, California, USA.
authors: Jon
authors: J
authors: Mulholland
authors: Department of Medicine, Division of Infectious Diseases and Geographic Medicine, and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA seinav@stanford.edu.
authors: Shirit
authors: S
authors: Einav
mesh_terms: D015153:Blotting, Western; D002460:Cell Line; D000069347:Erlotinib Hydrochloride; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008156:Luciferases; D008856:Microscopy, Fluorescence; D010957:Plasmids / Q000235:genetics; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D011758:Pyrroles / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D000077210:Sunitinib; D053586:Virus Internalization
chemical_list: D007211:Indoles; D047908:Intracellular Signaling Peptides and Proteins; D011758:Pyrroles; D011799:Quinazolines; D034741:RNA, Small Interfering; D000069347:Erlotinib Hydrochloride; D008156:Luciferases; C451304:AAK1 protein, human; C486325:GAK protein, human; D017346:Protein Serine-Threonine Kinases; D000077210:Sunitinib
references: J Biol Chem. 2005 Oct 21;280(42):35108-18
references: 16105844
references: J Gen Virol. 2006 Sep;87(Pt 9):2583-93
references: 16894197
references: J Biol Chem. 2011 Oct 7;286(40):35196-208
references: 21832070
references: PLoS Pathog. 2012;8(8):e1002845
references: 22916011
references: Traffic. 2003 Dec;4(12):885-90
references: 14617351
references: Science. 1995 Sep 29;269(5232):1872-5
references: 7569928
references: J Hepatol. 2013 Mar;58(3):583-92
references: 23104162
references: J Virol. 1993 Apr;67(4):1953-8
references: 8383220
references: Traffic. 2005 Dec;6(12):1103-13
references: 16262722
references: PLoS Pathog. 2009 Dec;5(12):e1000702
references: 20041214
references: FEBS Lett. 2003 Jul 10;546(2-3):385-90
references: 12832074
references: Curr Top Microbiol Immunol. 2000;242:55-84
references: 10592656
references: Mol Biol Cell. 2006 Dec;17(12):5298-308
references: 17035630
references: Nat Rev Mol Cell Biol. 2009 Sep;10(9):583-96
references: 19696796
references: J Med Virol. 2007 Jun;79(6):714-23
references: 17457918
references: PLoS Pathog. 2009 Feb;5(2):e1000310
references: 19229312
references: Mol Biol Cell. 2007 Aug;18(8):2991-3001
references: 17538018
references: J Cell Sci. 2005 Sep 15;118(Pt 18):4311-21
references: 16155256
references: J Biol Chem. 1996 May 17;271(20):12111-6
references: 8662627
references: J Virol. 2006 Nov;80(21):10579-90
references: 16928753
references: Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7271-6
references: 12761383
references: Nature. 2009 Feb 12;457(7231):882-6
references: 19182773
references: Nat Rev Microbiol. 2013 Oct;11(10):688-700
references: 24018384
references: EMBO J. 1988 Nov;7(11):3331-6
references: 2905261
references: J Antimicrob Chemother. 2011 Aug;66(8):1673-86
references: 21652618
references: J Cell Sci. 2001 Jan;114(Pt 2):353-65
references: 11148137
references: Annu Rev Cell Dev Biol. 2012;28:309-36
references: 22831640
references: Cell Host Microbe. 2013 Mar 13;13(3):302-13
references: 23498955
references: J Gen Virol. 2000 Jul;81(Pt 7):1631-48
references: 10859368
references: EMBO J. 2002 Oct 1;21(19):5017-25
references: 12356718
references: J Virol. 2006 Feb;80(4):1734-41
references: 16439530
references: Annu Rev Cell Dev Biol. 2004;20:153-91
references: 15473838
references: Antiviral Res. 1990 Oct-Nov;14(4-5):181-205
references: 2088205
references: J Struct Biol. 2009 Jul;167(1):1-10
references: 19358891
references: J Cell Biol. 2004 Oct 25;167(2):215-21
references: 15492044
references: Mol Biol Cell. 2007 Jul;18(7):2698-706
references: 17494869
references: J Biol Chem. 2001 Dec 7;276(49):46230-6
references: 11577110
references: Nat Rev Microbiol. 2007 Jun;5(6):453-63
references: 17487147
references: J Virol. 2004 Feb;78(3):1448-55
references: 14722300
references: Nat Biotechnol. 2008 Jan;26(1):127-32
references: 18183025
references: Cancer Res. 1997 Dec 15;57(24):5498-504
references: 9407958
references: Cell. 2006 Mar 10;124(5):997-1009
references: 16530046
references: Nature. 1998 Aug 20;394(6695):793-7
references: 9723620
references: Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11790-5
references: 18689690
references: Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10296-301
references: 15240878
references: Nat Cell Biol. 1999 Oct;1(6):376-82
references: 10559966
references: EMBO J. 1996 Nov 1;15(21):5789-95
references: 8918456
references: Traffic. 2008 Sep;9(10):1791-800
references: 18657069
references: J Virol. 2006 Jul;80(14):6964-72
references: 16809302
references: Science. 1998 Oct 30;282(5390):938-41
references: 9794763
references: Hepatology. 2007 Dec;46(6):1722-31
references: 18000990
references: J Virol. 2008 Apr;82(7):3555-60
references: 18234789
references: J Virol. 2012 Oct;86(20):10935-49
references: 22855500
references: Ann Intern Med. 2000 Feb 15;132(4):296-305
references: 10681285
references: J Virol. 2008 Sep;82(17):8316-29
references: 18579606
references: J Virol. 2009 Feb;83(4):2011-4
references: 19052094
references: J Hepatol. 2007 Mar;46(3):411-9
references: 17156886
references: Science. 2005 Jul 22;309(5734):623-6
references: 15947137
references: J Med Virol. 1999 Mar;57(3):223-9
references: 10022791
references: EMBO J. 2002 Sep 16;21(18):4915-26
references: 12234931
references: J Virol. 2012 Apr;86(8):4305-16
references: 22318146
references: J Cell Biol. 2002 Mar 4;156(5):791-5
references: 11877457
references: Genes Dev. 1997 Sep 1;11(17):2239-49
references: 9303539
references: Biosci Rep. 2014;34(4). pii: e00123. doi: 10.1042/BSR20140069
references: 24975939
references: J Virol. 2009 Aug;83(16):8012-20
references: 19515778
references: J Cell Biol. 2003 Sep 1;162(5):909-18
references: 12952941
references: J Gen Virol. 2006 Oct;87(Pt 10):2983-91
references: 16963757
references: J Cell Biol. 2003 Oct 27;163(2):203-8
references: 14581447
references: Curr Top Microbiol Immunol. 2013;369:321-42
references: 23463207
references: Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10777-82
references: 23754414
references: Liver Int. 2009 Jan;29 Suppl 1:74-81
references: 19207969
references: Semin Liver Dis. 2000;20(1):57-68
references: 10895432
references: J Virol. 2006 Jun;80(11):5308-20
references: 16699011
references: Am J Physiol Cell Physiol. 2011 Apr;300(4):C723-42
references: 21209361
references: Science. 2001 Feb 9;291(5506):1051-5
references: 11161218
references: Eur J Cell Biol. 2000 May;79(5):336-42
references: 10887964
references: PLoS Pathog. 2009 Apr;5(4):e1000394
references: 19390604
references: J Infect Dis. 2010 Jul 1;202(1):65-74
references: 20486856
references: J Virol. 2006 Dec;80(23):11571-8
references: 17005647
references: Med Microbiol Immunol. 1992;181(5):293-300
references: 1335546
references: Genome Res. 2004 Oct;14(10B):2128-35
references: 15489335
references: J Virol. 2007 Apr;81(7):3162-9
references: 17215280
references: FASEB J. 2009 Nov;23(11):3780-9
references: 19608626
references: Antivir Ther. 1996 Jan;1(1):9-20
references: 11322261
references: Nat Med. 2012 Feb;18(2):281-5
references: 22231557
references: Nature. 2007 Apr 12;446(7137):801-5
references: 17325668
references: J Virol. 2007 Jan;81(1):374-83
references: 17050612
references: J Exp Med. 2003 Mar 3;197(5):633-42
references: 12615904
references: Nat Med. 2011 May;17(5):589-95
references: 21516087
references: J Virol. 2006 Nov;80(22):11074-81
references: 16956946
references: J Virol. 2007 Oct;81(19):10220-31
references: 17634240
references: Traffic. 2002 Jun;3(6):428-39
references: 12010461
references: J Biol Chem. 2011 May 27;286(21):18720-30
references: 21464124
references: J Cell Sci. 2006 Sep 15;119(Pt 18):3719-21
references: 16959901
references: J Virol. 2010 Nov;84(22):11905-15
references: 20844034
references: J Virol. 2013 Jun;87(12):6866-75
references: 23576506
references: J Cell Biol. 2000 Dec 11;151(6):1345-52
references: 11121447
references: J Med Chem. 1963 Mar;6:145-53
references: 14188786
references: J Gen Virol. 2014 Dec;95(Pt 12):2658-67
references: 25096815
references: Traffic. 2009 Feb;10(2):235-45
references: 19054389
references: J Biol Chem. 2008 Feb 29;283(9):5510-7
references: 18158287
references: Cell Commun Signal. 2009 Oct 08;7:24
references: 19814798
references: J Virol. 2007 Nov;81(22):12465-71
references: 17804490
references: EMBO J. 2008 Apr 9;27(7):970-81
references: 18354494
references: Nat Methods. 2011 Dec;8(12):990-2
references: 22127214
references: J Virol. 2002 Jul;76(14):6919-28
references: 12072493
references: PLoS One. 2009;4(8):e6561
references: 19668344
references: Nature. 2003 Mar 6;422(6927):37-44
references: 12621426
references: Mol Cancer Ther. 2009 Sep;8(9):2559-65
references: 19723886
references: Mol Biol Cell. 2004 Aug;15(8):3698-708
references: 15155807
references: J Virol. 2012 Jul;86(13):7256-67
references: 22532692
references: J Virol. 2006 Mar;80(5):2418-28
references: 16474148
references: J Virol. 2004 Aug;78(16):8496-505
references: 15280458
references: J Virol. 2008 Sep;82(17):8797-811
references: 18579596